AstraZeneca plc (LON:AZN) today announced that the European Commission has approved an update to the marketing authorisation for Forxiga to include positive cardiovascular outcomes and renal data from the Phase..
AstraZeneca plc (LON: AZN) today announced that the US Food and Drug Administration has issued a complete response letter regarding the supplemental New Drug Application for Farxiga (dapagliflozin) as an..
AstraZeneca (LON: AZN) has today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung..
AstraZeneca plc (LON: AZN) has today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to add a self-administration option..
AstraZeneca plc (LON: AZN) has today announced positive overall survival results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage small cell lung cancer, a disease with significant..
AstraZeneca plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US today announced that Lynparza has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated advanced..
AstraZeneca plc (LON:AZN) today announced that Bevespi Aerosphere has been approved in Japan as a fixed-dose, long-acting dual bronchodilator to relieve symptoms in patients with chronic obstructive pulmonary disease. This..
AstraZeneca plc (LON: AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) have today announced that the European Commission (EC)..
AstraZeneca plc (LON: AZN) has today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association Annual Congress in Amsterdam, showing Calquence..
AstraZeneca plc (LON:AZN) today announced positive results from the Phase III ELEVATE-TN trial of Calquence(acalabrutinib) in patients with previously-untreated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in..
AstraZeneca Plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced detailed results from the Phase III POLO..
AstraZeneca Plc (LON:AZN) today announced top-line results from the pooled cardiovascular (CV) safety analyses of the global Phase III programme for roxadustat, a first-in-class hypoxia-inducible-factor prolyl hydroxylase inhibitor (HIF-PHI). The..
AstraZeneca Plc (LON:AZN) and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug..
AstraZeneca Plc (LON:AZN) today announced positive results from the Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL). Results showed a statistically-significant and clinically-meaningful..
AstraZeneca PLC (LON:AZN), The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and..
AstraZeneca Plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the Committee for Medicinal Products for..
AstraZeneca PLC (LON:AZN), today announced Q1 2019 results. Results in the first quarter were supported by Product Sales growth of 10% (14% at CER1) to $5,465m, a reflection of the..
AstraZeneca Plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced the European Commission has approved Lynparza (olaparib)..
AstraZeneca Plc (LON:AZN) and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration..
AstraZeneca Plc (LON:AZN) has entered into a global development and commercialisation collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate (ADC) and..
